Pharming Q2 EPS $(0.002) Down From $0.002 YoY, Sales $74.10M Up From $54.90M YoY
Portfolio Pulse from Benzinga Newsdesk
Pharming (NASDAQ:PHAR) reported a Q2 EPS of $(0.002), down from $0.002 YoY, with sales of $74.10M, up from $54.90M YoY, marking a 34.97% increase.
August 01, 2024 | 5:42 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pharming reported a Q2 EPS of $(0.002), a decrease from $0.002 YoY. However, sales increased by 34.97% to $74.10M from $54.90M YoY.
While the EPS has decreased, the significant increase in sales by 34.97% may offset the negative sentiment from the EPS drop. Investors might view the revenue growth positively, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100